Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 1

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
 and outstanding 
     -  
     - 
  
    Common stock, $0.0001 par value; 20,000,000 shares authorized; 786,902 and 536,908 shares issued and outstanding, respectively 
     77  
     53 
  
    Additional paid in capital 
     107,467,603  
     105,998,412 
  
    Stock payable 
     -  
     - 
  
    Accumulated deficit 
     (107,296,300) 
     (103,438,099)

    Total Stockholders’ Equity 
     171,380  
     2,560,366 
  
    Total Liabilities and Stockholders’ Equity 
    $1,964,108  
    $4,452,362 

The accompanying notes are an integral part of
these unaudited condensed consolidated financial statements.

1

ENDRA Life Sciences Inc.

Condensed Consolidated Statement of Operations

(Unaudited)

    Three Months Ended  
    Three Months Ended  
    Nine Months Ended  
    Nine Months Ended 

    September 30,  
    September 30,  
    September 30,  
    September 30, 

    2025  
    2024  
    2025  
    2024 
  
    Operating Expenses 

    Research and development 
    $432,113  
    $794,444  
    $1,341,859  
    $2,552,336 
  
    Sales and marketing 
     45,285  
     83,157  
     183,110  
     484,769 
  
    General and administrative 
     893,305  
     631,413  
     2,616,106  
     3,483,303 
  
    Total operating expenses 
     1,370,703  
     1,509,014  
     4,141,075  
     6,520,408 

    Operating loss 
     (1,370,703) 
     (1,509,014) 
     (4,141,075) 
     (6,520,408)

    Other Income (Expenses) 

    Other income (expense) 
     42,018  
     65,528